Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Red Cedar Wellness Center
mi
from
Bellevue, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Red Cedar Wellness Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Seattle Integrative Oncology at Providence Integrative Cancer Care
mi
from
Lacey, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Seattle Integrative Oncology at Providence Integrative Cancer Care
mi
from
Lacey, WA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Seattle Cancer Treatment & Wellness Center
mi
from
Renton, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Seattle Cancer Treatment & Wellness Center
mi
from
Renton, WA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Seattle Integrative Oncology at Institute of Complementary Medicine
mi
from
Seattle, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Seattle Integrative Oncology at Institute of Complementary Medicine
mi
from
Seattle, WA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Tree of Health Integrative Medicine
mi
from
Woodinville, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Tree of Health Integrative Medicine
mi
from
Woodinville, WA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Bastyr Integrative Oncology Research Center
mi
from
Kenmore, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Bastyr Integrative Oncology Research Center
mi
from
Kenmore, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Beebe Medical Center
mi
from
Lewes, DE
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Baptist MD Anderson Cancer Center
mi
from
Jacksonville, FL
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Baptist MD Anderson Cancer Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Northwestern University
mi
from
Chicago, IL
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Franciscan Health Indianapolis
mi
from
Indianapolis, IN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Franciscan Health Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Reid Health
mi
from
Richmond, IN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Reid Health
mi
from
Richmond, IN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Saint Luke's Regional Medical Center
mi
from
Sioux City, IA
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Saint Luke's Regional Medical Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Union Hospital of Cecil County
mi
from
Elkton, MD
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Fairview Ridges Hospital
mi
from
Burnsville, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Fairview Ridges Hospital
mi
from
Burnsville, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Mercy Hospital
mi
from
Coon Rapids, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Mercy Hospital
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Fairview Southdale Hospital
mi
from
Edina, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Fairview Southdale Hospital
mi
from
Edina, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Unity Hospital
mi
from
Fridley, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Unity Hospital
mi
from
Fridley, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Hutchinson Area Health Care
mi
from
Hutchinson, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Hutchinson Area Health Care
mi
from
Hutchinson, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Saint John's Hospital - Healtheast
mi
from
Maplewood, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Saint John's Hospital - Healtheast
mi
from
Maplewood, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
North Memorial Medical Health Center
mi
from
Robbinsdale, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
North Memorial Medical Health Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Park Nicollet Clinic - Saint Louis Park
mi
from
Saint Louis Park, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Park Nicollet Clinic - Saint Louis Park
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Regions Hospital
mi
from
Saint Paul, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Regions Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
United Hospital
mi
from
Saint Paul, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
United Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Saint Francis Regional Medical Center
mi
from
Shakopee, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Saint Francis Regional Medical Center
mi
from
Shakopee, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Lakeview Hospital
mi
from
Stillwater, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Lakeview Hospital
mi
from
Stillwater, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Ridgeview Medical Center
mi
from
Waconia, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Ridgeview Medical Center
mi
from
Waconia, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Rice Memorial Hospital
mi
from
Willmar, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Rice Memorial Hospital
mi
from
Willmar, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Carolinas HealthCare System NorthEast
mi
from
Concord, NC
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Carolinas HealthCare System NorthEast
mi
from
Concord, NC
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Carolinas HealthCare System Union
mi
from
Monroe, NC
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Carolinas HealthCare System Union
mi
from
Monroe, NC
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Carolinas HealthCare System Cleveland
mi
from
Shelby, NC
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Carolinas HealthCare System Cleveland
mi
from
Shelby, NC
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Grandview Hospital
mi
from
Dayton, OH
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Grandview Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Good Samaritan Hospital - Dayton
mi
from
Dayton, OH
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Good Samaritan Hospital - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Miami Valley Hospital
mi
from
Dayton, OH
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Samaritan North Health Center
mi
from
Dayton, OH
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Samaritan North Health Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Dayton NCI Community Oncology Research Program
mi
from
Dayton, OH
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Dayton NCI Community Oncology Research Program
mi
from
Dayton, OH
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated:  3/21/2018
Blanchard Valley Hospital
mi
from
Findlay, OH
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Status: Enrolling
Updated: 3/21/2018
Blanchard Valley Hospital
mi
from
Findlay, OH
Click here to add this to my saved trials